NCT05199194 Randomization to Endovascular Treatment Alone or Preceded by Systemic Thrombolysis With Tenecteplase in Ischemic Stroke

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.

This trial targets 398 participants in total. It began in 2022-05-27 with a primary completion date of 2026-07.

Brief Summary

A phase III randomized, multi-center, double-blinded, placebo-controlled clinical trial that will examine two strategies for the treatment of acute ischemic stroke associated with a large vessel anterior occlusion within 4.5 hours from symptoms onset: direct endovascular treatment vs. endovascular treatment preceded by intravenous tenecteplase.

Eligibility Criteria

Inclusion Criteria: * Acute ischemic stroke where a patient is eligible for IV thrombolytic treatment within 4.5 hours of stroke onset. * No significant pre-stroke functional disability (mRS ≤ 1) * Baseline NIHSS scores obtained before randomization must be equal to or higher than 6 points * Age equal ≥ 18 and =\< 85 years * Occlusion (TICI 0-1) of the ICA or proximal MCA segments (M1 or M2) suitable for endovascular treatment, as evidenced by CTA, MRA, or angiogram, with or without concomitant cervical carotid stenosis or occlusion. * Patient randomized within 4.5 hours of symptom onset. Symptoms onset is defined as the point in time the patient was last seen well (at baseline). Treatment start is defined as groin puncture, max 90 minutes after randomization. * Patients who have woken up with the symptoms and who have a mismatch FLAIR-DWI according to the WAKE-UP Trial will be considered as having a time window of \<4.5h. * Informed consent obtained from the patient or acceptable patient surrogate. Exclusion Criteria: * Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR \> 1.7 or direct oral anticoagulants such as thrombin antagonists (ex: dabigatran) or X factor (ex: rivaroxaban, apixaban, edoxaban) at the least 48 hours. * Baseline platelet count \< 100.000/μL * Baseline blood glucose of \< 50mg/dL or \> 400mg/dl * Severe, sustained hypertension (SBP \> 185 mm Hg or DBP \> 110 mm Hg) NOTE: If the blood pressure can be successfully reduced and maintained at the acceptable level using AHA guidelines recommended medication (including iv antihypertensive drips), the patient can be enrolled. * Patients in coma (NIHSS item of consciousness \>1) (Intubated patients for transfer could be randomized only in case an NIHSS is obtained by a neurologist prior transportation). * Seizures at stroke onset which would preclude obtaining a baseline NIHSS * Serious, advanced, or terminal illness with anticipated life expectancy of less than one year. * History of life-threatening allergy (more than rash) to contrast medium. * Subjects who has received IV t-PA treatment before the randomization. * Renal failure with serum creatinine ≥ 3 mg/dl * Woman of childbearing potential who is known to be pregnant or who has a positive pregnancy test on admission. * Subject participating in a study involving an investigational drug or device that would impact this study. * Cerebral vasculitis, endocarditis or subarachnoid hemorrhage. * Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations. * Unlikely to be available for 90-day follow-up (e.g. no fixed home address, visitor from overseas). * Hypodensity on CT more than one third of MCA territory or hypersignal in more than one third of MCA territory on MR-DWI. * ASPECTS score \< 6 (no contrast at least 5 mm cut imaging on CT) or on MR-DWI sequence. * CT or MR evidence of hemorrhage (the presence of \< 5 GRE, SWI, SWAN microbleeds is allowed). * Significant mass effect with midline shift. * Evidence of ipsilateral carotid occlusion, high grade stenosis or arterial dissection in the extracranial or petrous segment of the internal carotid artery that cannot be treated or will prevent access to the intracranial clot or excessive tortuosity of cervical vessels precluding device delivery/deployment. * Subjects with occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior/posterior circulation). * Evidence of intracranial tumor (except small meningioma).

Contact & Investigator

Frequently Asked Questions

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.